SignaLife

Company Overview

Snapshot

Founded in March 2021 by Roy Nissim, SignaLife operates with 1–10 employees. The company has raised $2.7 million across three funding rounds and secured a grant from the Israel Innovation Authority in April 2023. SignaLife is currently conducting its second clinical trial in Sheba Medical Center’s NICU, with promising initial pH results from the first baby recruited in April 2025.

Business overview

SignaLife is a technology company specializing in Health Tech & Life Sciences, developing AI-powered optic sensors for medical and well-being applications. The company's core technology provides non-invasive and continuous monitoring of pH and blood gases for patients in ICU and NICU settings, aiming to reduce infection risks, minimize blood draws, and enhance treatment decisions. SignaLife serves the healthcare industry, particularly providers, with solutions in medical devices and monitoring.

Company Intelligence Q&A

What is SignaLife's primary focus?

SignaLife develops non-invasive, continuous blood gas and pH sensors using AI optic technology for medical and well-being applications, primarily targeting patients in ICU and NICU environments.

When was SignaLife founded?

SignaLife was founded in March 2021.

Who is a co-founder of SignaLife?

Roy Nissim is a co-founder and CSO of SignaLife.

What is the current stage of SignaLife's product development?

SignaLife's product is currently in the clinical trial stage. The company recruited the first baby in its second clinical trial at Sheba Medical Center’s NICU in April 2025, following initial human trials in Assuta Ashdod ICU.

Has SignaLife received any non-equity funding?

Yes, in April 2023, SignaLife secured a grant from the Israel Innovation Authority.